



3.4.16 Hospital Pharmacy Group*



Strategic Objective

The Hospital Pharmacy group aims to investigations on pharmacotherapy focused on both, researches on treatments and innovation technology related to the medication use process in order to optimize clinical practice.

Research lines

1. Evaluation of Drugs - Real World Outcomes, especially those associated with high economic impact or with limited clinical evidence. In this regard, our target is to investigate on the following fields:
 - Coagulopathies
 - Oncology
 - Biologic therapies
 - Infectious diseases
 - Rare diseases

- Gene therapy
 - Link between the parasympathetic and innate immune systems.
2. Investigation on strategies for early detection and prevention of medication errors either in patients with critical illness and patients with complex chronic conditions.
 3. Analysis of the impact on medication adherence and health outcomes of innovation in new technologies applied to the medication use process:
 - Telepharmacy programs including or not medications home delivery. Evaluation of their impact on medication adherence and health outcomes in different pathologies such as migraine, multiple sclerosis, prostate cancer and asthma.
 - Development and evaluation of digital health tools applied to congenital coagulopathies and its impact in terms of adherence and treatment cost-effectiveness improvement.
 - Research on the effect of predictive analytics and big data on clinical decision making and pharmaceutical outcomes optimization.
 - Identification of signalling pathways connecting nicotinic alpha7 receptors and negative regulators of TLR-mediated inflammation in human macrophages.
 4. Development of new drugs: Advanced therapies

* Group recently created, december 2020